Nicholas Goldner
Venture Partner at Alix Ventures
San Francisco Bay Area
Writes $200K – $300K checks · typically $250K
FoundedResistanceBio · YC
About
Nick Goldner is a founder and investor with a PhD in Molecular and Cellular Biology from Washington University in St. Louis, where he identified the molecular drug target of the antibiotic Daptomycin. He founded Viosera Therapeutics, an antibiotic company where he led IP strategy resulting in issued patents across the US, EU, China, and Japan, and later founded resistanceBio, an oncology services company. He now serves as a Venture Partner at Alix Ventures, focusing on early-stage life science and TechBio startups, and was previously a venture partner at Pioneer Fund covering biotech.
Invests in
AI & Machine LearningBiotechHealthtech
Experience
- Alix VenturesVenture Partnercurrent2025 — presentSan Francisco Bay Area
- Angel InvestorAngel Investorcurrent2019 — present
- Pioneer FundVenture Partnercurrent2019 — presentSan Francisco Bay Area
- resistanceBioChief Marketing Officer and SVP of Product2024Menlo Park, California, United States
- resistanceBioFounder2021 — 2024Menlo Park, California, United States
- resistanceBioChief Executive Officer2021 — 2023Menlo Park, California, United States
- Viosera TherapeuticsCEO and Co-founder2016 — 2021Greater St. Louis
Education
- Y Combinator
- Washington University School of Medicine in St. LouisDoctor of Philosophy, Evolution and Molecular Biology
- Washington University School of Medicine in St. LouisDoctor of Philosophy
Skills & more
+1 more
GeneticsLanguages English · German
From Nicholas's professional profile.
